An observational study in Infertility, sponsored by Ferring Pharmaceuticals. Active, not recruiting at 31 sites in 5 countries. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Ferring Pharmaceuticals · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Infertility by Ferring Pharmaceuticals — none open to participants now, 2 under way, none of them phase 3. Infertility · Ferring Pharmaceuticals.
Among the 39 studies in Infertility by Ferring Pharmaceuticals, this one is the 3rd largest by enrollment of the 12 observational ones that give a count, is one of 2 that started in 2024, is one of 12 observational ones, and was the 36th registered.
2,090 studies on the registry are indexed under Infertility; 356 are open to participants now.
Browse Infertility studies →None of the 39 studies in Infertility by Ferring Pharmaceuticals is open now. The open studies under Infertility, anywhere →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 20 Years and older · female.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 12 · Phase 4 6
First in 2004; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,526 is above the median of 200 across 592 observational studies indexed under Infertility.
Median enrollment 220 across the 27 interventional studies, 355 across the 12 observational. Of the 35 that completed or were terminated, 18 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ferring Pharmaceuticals is the lead sponsor of 249 studies on the registry; 4 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 14 (93%) have results posted.
1 of the studies in Infertility by Ferring Pharmaceuticals that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06561958Ferring PharmaceuticalsProspective, Multi-centre, Non-Interventional Study to Investigate the Effectiveness of REKOVELLE® for Ovarian Stimulation for Asian Women in Real World Settings | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 39 studies in Infertility by Ferring Pharmaceuticals, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary objective is to investigate the effectiveness of REKOVELLE® in women undergoing their first REKOVELLE® ovarian stimulation treatment in real world practice in Asian countries.
Approximately 1500 patients prescribed REKOVELLE for the first time for controlled overian stimulation (COS) will be enrolled in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants prescribed REKOVELLE for the first time for controlled ovarian stimulation.
Drug: REKOVELLE
Individualised dosing regiment of REKOVELLE in routine clinical practice.
Cumulative live birth rate
Cumulative live birth rate defined as delivery of at least 1 live fetus after 20 completed weeks of gestation, combined fresh and frozen embryo transfers within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle.
Time frame: Up to 12 months
The Luteinising hormone (LH) surge suppression protocol
Treatment pattern will be measured by analysing the Lutenising hormone (LH) surge suppression protocol.
Time frame: Up to 22 days
Daily Dosage
Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of daily dosage.
Time frame: Up to 22 days
Stimulation Duration
Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of stimulation duration.
Time frame: Up to 22 days
Total Dosage
Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of total dosage.
Time frame: Up to 22 days
Trigger Protocol
Treatment pattern will be measured by analysing the trigger protocol.
Time frame: Up to 22 days
Luteal phase support protocol
Treatment pattern will be measured by analysing the luteal phase support protocol.
Time frame: Up to 22 days
Number of oocytes retrieved
Number of oocytes retrieved at oocyte retrieval
Time frame: Up to 22 days
Number of Metaphase II (MII) oocytes
Number of MII oocytes at oocyte retrieval (only applicable for Intracytoplasmic sperm injection (ICSI))
Time frame: Up to 22 days
Number of embryos
Number of embryos on Day 3 after oocyte retrieved
Time frame: Day 3 after oocyte retrieval
Number of Blastocysts
Number of Blastocysts on Day 5 after oocyte retrieved
Time frame: Day 5 after oocyte retrieval
Number of embryos transferred
Embryos transferred in fresh and/or frozen transfer cycles
Time frame: Up to 28 days
Number of blastocysts transferred
Blastocysts transferred in fresh and/or frozen transfer cycles
Time frame: Up to 28 days
Implantation rate
Number of gestational sacs, embryos or blastocysts transferred
Time frame: Up to 28 days
Positive human chorionic gonadotropin (hCG) rate
Positive human chorionic gonadotropin (hCG) rate analysed using serum or urine hCG test 11-15 days after transfer
Time frame: 11 to 15 days after transfer
Clinical Pregnancy rate
Clinical pregnancy rate (at least 1 gestational sac 4-5 weeks after transfer)
Time frame: 4 to 5 weeks after transfer
Vital Pregnancy
Vital pregnancy rate (at least 1 intrauterine gestational sac with fetal heartbeat 4-5 weeks after transfer)
Time frame: 4 to 5 weeks after transfer
Ongoing pregnancy rate
Ongoing pregnancy rate (at least 1 intrauterine viable fetus 9-11 weeks after transfer)
Time frame: 9 to 11 weeks after transfer
Time to pregnancy
Time to pregnancy from start date of ovarian stimulation to confirmation of clinical pregnancy
Time frame: 4 to 5 weeks after transfer
Live birth rate
Live birth is defined as delivery of at least 1 live fetus after 20 completed weeks of gestation within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle.
Time frame: More than 20 weeks after transfer
Multiple pregnancy rate
More than 1 gestational sac with fetal heart beat 4-5 weeks after transfer
Time frame: 4 to 5 weeks after transfer
Spontaneous abortion rate
Spontaneous abortion is defined as positive hCG test but all intrauterine gestational sacs without fetal heart beat as documented by ultrasound, or there are no viable fetuses observed by ultrasound
Time frame: Up to 10-11 weeks after transfer
Ectopic pregnancy rate
Ectopic pregnancy is defined as extrauterine gestational sac with or without fetal heart beat as documented by ultrasound or surgery.
Time frame: Up to 10-11 weeks after transfer
Estradiol Hormone levels
Estradiol hormone levels before stimulation and at the end of stimulation day
Time frame: Up to 20 days
Progesterone Hormone levels
Progesterone hormone levels before stimulation and at the end of stimulation day
Time frame: Up to 20 days
Cycle cancellation rate and the reason for cycle cancellation
Date when the investigator decides to cancel cycle before oocyte pick up (due to poor ovarian response, excessive ovarian response, any illness which prevents oocyte collection procedure, subject not taking hCG injection at the correct time, subject choice, other) or after oocyte pick-up (due to no oocytes collected, no oocytes fertilized, abnormal fertilization, abnormal embryo development, no embryo development, ovarian hyperstimulation syndrome (OHSS), subject choice, any other specified reason)
Time frame: Up to 28 days
Transfer cancellation rate and the reason for transfer cancellation
Transfer cancellation rate and the reason for transfer cancellation (no embryo available for transfer, risk of OHSS, endometrium not receptive, high progesterone level, adverse event, any other specified reason for transfer cancellation).
Time frame: Up to 28 days
Frequency and severity of adverse drug reactions (ADRs) and serious adverse events (SAEs)
Frequency and severity of ADRs and SAEs as defined by the investigator
Time frame: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
Preventive interventions for ovarian hyperstimulation syndrome (OHSS)
Preventive interventions decided by the investigator (Triggering of final follicular maturation with GnRH agonist and fresh embryo/blastocyst transfer or cryopreservation, Cancellation of fresh embryo/blastocyst transfer)
Time frame: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.
Number of subjects with mild / moderate / severe ovarian hyperstimulation syndrome (OHSS)
Number of subjects with mild / moderate / severe OHSS, defined by the investigator
Time frame: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for May 2027, 32 months after the start.
Of 240 observational studies under Infertility, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 99. This study's planned 32 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.